ASXL3: A Potential Drug Target and Biomarker for KIAA1713 in Cancer

Target Name: ASXL3

NCBI ID: G80816

ASXL3

ASXL3: A Potential Drug Target and Biomarker for KIAA1713 in Cancer

Abstract:

ASXL3, a gene encoding a protein with potential drug targets and biomarkers, has been identified in various studies. Its expression has been observed in various types of cancer, including breast, lung, and ovarian cancer. Additionally, ASXL3 has been shown to play a role in the development and progression of cancer. This review aims to discuss the current understanding of ASXL3 as a potential drug target and biomarker for cancer.

Introduction:

Cancer is a leading cause of death worldwide, with over 20 million new cases being diagnosed each year. The development and progression of cancer are complex and involve the interplay of multiple factors, including genetic and epigenetic alterations, as well as signaling pathways. ASXL3, a gene encoding a protein with potential drug targets and biomarkers, has been identified in various studies as having relevance to cancer.

Expression of ASXL3 in cancer:

ASXL3 has been observed to be expressed in various types of cancer, including breast, lung, and ovarian cancer. In breast cancer, ASXL3 has been shown to promote the growth and invasiveness of cancer cells. Additionally, it has been shown to contribute to the development of resistance to chemotherapy in breast cancer.

In lung cancer, ASXL3 has been shown to promote the formation of airwayal stem cells, which can give rise to new cancer cells. Furthermore, ASXL3 has been shown to contribute to the development of lung cancer stem cells.

In ovarian cancer, ASXL3 has been shown to promote the growth and survival of cancer cells. Additionally, it has been shown to contribute to the development of resistance to chemotherapy in ovarian cancer.

Drug targeting of ASXL3:

ASXL3 has been shown to be a potential drug target in cancer. Several studies have shown that inhibiting ASXL3 can lead to the inhibition of the growth and survival of cancer cells. Additionally, several inhibitors of ASXL3 have been shown to be effective in preclinical studies in cancer.

One of the most promising ASXL3 inhibitors is the drug IPT-008, which is currently in clinical trials for the treatment of various types of cancer. IPT-008 is a small molecule inhibitor of ASXL3 that has been shown to be effective in preclinical studies in cancer.

Biomarker potential of ASXL3:

ASXL3 has also been shown to be a potential biomarker for cancer. Its expression has been observed to be associated with the development and progression of cancer. Additionally, ASXL3 has been shown to play a role in the regulation of cellular processes that are relevant to cancer development, such as cell growth, apoptosis, and angiogenesis.

Conclusion:

In conclusion, ASXL3 has been shown to be a potential drug target and biomarker for cancer. Its expression has been observed in various types of cancer and has been shown to contribute to the development and progression of cancer. Additionally, ASXL3 has been shown to be a promising candidate for drug targeting in cancer. Further research is needed to fully understand the role of ASXL3 in cancer and to develop effective ASXL3 inhibitors for cancer treatment.

Protein Name: ASXL Transcriptional Regulator 3

Functions: Putative Polycomb group (PcG) protein. PcG proteins act by forming multiprotein complexes, which are required to maintain the transcriptionally repressive state of homeotic genes throughout development. PcG proteins are not required to initiate repression, but to maintain it during later stages of development. They probably act via methylation of histones, rendering chromatin heritably changed in its expressibility (By similarity)

The "ASXL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ASXL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets